{
  "name": "Buspirone",
  "genericName": "buspirone",
  "brandNames": ["BuSpar"],
  "tags": ["Anxiolytic", "5-HT1A Partial Agonist"],
  "dosing": {
    "adult_acute": "7.5 mg BID (or 5 mg TID)",
    "adult_maintenance": "15-30 mg/day divided BID-TID; max 60 mg/day",
    "notes": "Non-benzodiazepine anxiolytic; 2-4 weeks for full effect; no abuse potential; no withdrawal; must be dosed regularly (not PRN)",
    "canadian_clinical": {
      "starting_dose": "5 mg TID or 7.5 mg BID",
      "titration_schedule": "Increase by 5 mg/day every 2-3 days to 15-30 mg/day",
      "max_dose_evidence": "60 mg/day",
      "max_dose_practice": "30-60 mg/day divided BID-TID",
      "inpatient_strategy": "Start 7.5-15 mg BID; increase every 2-3 days to 30-45 mg/day",
      "outpatient_strategy": "Start 7.5 mg BID; increase weekly; counsel that effect takes 2-4 weeks (not immediate like benzodiazepines)"
    }
  },
  "warnings": [
    "Delayed onset (2-4 weeks) - NOT for acute anxiety or PRN use",
    "NOT a benzodiazepine - will NOT prevent benzodiazepine withdrawal",
    "Generally well-tolerated; side effects: dizziness, headache, nausea",
    "No abuse potential, no dependence, no withdrawal",
    "May cause serotonin syndrome if combined with other serotonergic agents",
    "Does NOT help panic attacks or acute anxiety - for generalized anxiety only"
  ],
  "cautions": {
    "renal": "Reduce dose by 25-50% in severe renal impairment",
    "hepatic": "Reduce dose by 25-50% in hepatic impairment",
    "pregnancy": "Pregnancy Category B; limited data but likely lower risk than benzodiazepines"
  },
  "citations": ["BuSpar FDA Label", "CANMAT Anxiety Guidelines", "NICE GAD Guidelines"]
}
